Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Mirror Image who wrote (1837)	4/11/2016 12:56:27 PM
From: mokelumne river	Respond to of 2026

With my eyes going back and forth between your list and the 10K: Sandoz has Finland, Denmark, and Norway Recordati owns Ireland and Portugal, and has a lock on eastern Europe that would include Poland, Slovakia and Czech Ferring has all of Latin America that would include Mexico Elis licensed Gulf countries and the non-Israeli ME that would include Kuwait, Lebanon, Saudi Arabia and UAE Of your list of thirteen, five have approved Vitaros per the 10K including Ireland and Portugal with Recordati and Finland, Denmark, and Norway with Sandoz. So the remaining eight countries on your list have a ways to go before launching. NOTE, the corporate presentation states that Vitaros has been "Approved in 22 countries in Europe under the DCP, of which 17 have further approved Vitaros for commercialization at the national phase level"...however where is the list of the 17 that are ready for commercialization implying ready to launch? I think the biggie on your list is Mexico which will open up Latin America. Unfortunately, Latin America will probably wait for the FDA, which is another reason why FDA approval is so important. I hope Mexico is ready to launch and its inclusion was not just a sloppy statement in the presentation.

To: Mirror Image who wrote (1837)	4/11/2016 1:17:28 PM
From: mokelumne river	Read Replies (2) \| Respond to of 2026

Now that you have me reading the corporate presentation, it states on page 13: >Allergan retains the right to launch a future AG under a profit share structure with Apricus< What is "AG"? Is that shorthand for a separate "agreement"? Also, I get irritated with statements like this, also on page 13: >If Allergan elects to opt-in, Apricus may receive up to a total of $25 million in upfront and potential regulatory milestones, plus a double-digit royalty< We all know that the upfront could be as little as $1 million (or less) with the remaining $24 million in regulatory milestones payable who knows when. I did like the statement on page 14 that >no additional clinical studies (are) expected<. If they say that a few more times, even PR might become a believer.